Mitochondrial respiratory complex II utilizes succinate, key substrate of the Krebs cycle, for oxidative phosphorylation, which is essential for glucose metabolism. Mutations of complex II cause cancers and mitochondrial diseases, raising a critical question of the (patho-)physiological functions. To address the fundamental role of complex II in systemic energy metabolism, we specifically knockout SDHB in mice liver, a key complex II subunit that tethers the catalytic SDHA subunit and transfers the electrons to ubiquinone, and found that SHDB deficiency abolishes the assembly of complex II without affecting other respiration complexes while largely retaining SDHA stability. SHDB ablation reprograms energy metabolism and hyperactivates the glycolysis, Krebs cycle and β-oxidation pathways, leading to catastrophic energy deficit and early death. Strikingly, sucrose supplementation or high fat diet resumes both glucose and lipid metabolism and prevent early death. Also, SDHB deficient mice are completely resistant to high fat diet induced obesity. Our findings reveal that the unanticipated role of complex II orchestrating both lipid and glucose metabolisms, and suggest that SDHB is an ideal therapeutic target for combating obesity.
Introduction
Mitochondria are cellular centers for ATP production via the Krebs cycle and oxidative phosphorylation (OXPHOS). They also serve as a central regulator for cell physiology, from the synthesis of intermediary metabolites and ROS production to modulation of cell death pathways. OXPHOS comprises four respiratory complexes, which can form a supercomplex depending on the energy status within a cell. Complex II, also named succinate dehydrogenase (SDH), is a key enzymatic complex that catalyzes the oxidation of succinate to fumarate in Krebs cycle. Complex II is a highly conserved heterotetrameric protein complex consisting of four nuclear-encoded subunits SDHA, SDHB, SDHC, and SDHD [1, 2] . SDHC and SDHD are embedded in the inner mitochondrial membrane, and the SDHC/SDHD dimer binds the peripheral membrane protein SDHB, which tethers the catalytic SDHA subunit so that it faces the mitochondrial matrix [3] . SDHA harbors a covalently bound FAD cofactor that is required for the oxidation of succinate [4] . The two electrons that result from succinate oxidation are channeled through the three iron-sulfur clusters in SDHB to ubiquinone [5] . Complex II is thus unique and functions at the crossroads of the Krebs cycle and OXPHOS pathways [6] . The genes encoding complex II subunits were found to be mutated in various types of tumor, such as paraganglioma (PGL) [7] , pheochromocytoma (PHEO) [8] , gastrointestinal stromal tumor (GIST) [9] , renal cell carcinoma and Leigh syndrome [10] . Complex II is also reported to be a tumor suppressor [11] [12] [13] . Complex II is thus considered as a therapeutic target for highly debilitating pathologies including cancer, Parkinson's disease [14] and inflammatory diseases, with potential clinical relevance. Ischemic accumulation of succinate via reversal of its SDH activity drives the mitochondrial ROS production upon reperfusion that underlies IR injury in a range of tissues [15] . Such accumulation of succinate also plays a role in inflammatory and hypoxic signaling [16] .
Mitochondria are the principal sites for β-oxidation, which breaks down fatty acids for energy production. The final products of fatty acid β-oxidation are acetyl-CoA, NADH, and FADH2, which enter into Krebs cycle and OXPHOS for ATP production. The metabolism of fatty acid and glucose are tightly linked through gluconeogenesis and de novo lipid synthesis pathways in liver and other metabolic organs, depending on the feeding status. Under nutrient-rich conditions, glycolytic products are used to synthesize fatty acids in liver through de novo lipogenesis, and the lipids are stored in lipid droplets in fat tissue, or secreted into the circulation as VLDL particles. In the fasted state, the liver produces glucose through breakdown of glycogen and gluconeogenesis. Prolonged fasting promotes lipolysis in adipose tissue; the released fatty acids are converted into ketone bodies in the liver using acetyl-CoA produced through mitochondrial β oxidation [17] . The liver thus lies at the center of energy metabolism within our bodies and orchestrates the systemic metabolic balance of glucose, lipids, and amino acid. Aberrant energy metabolism in the liver causes metabolic syndromes including insulin resistance, diabetes, and nonalcoholic fatty liver diseases [18] .
Mitochondria are highly enriched in liver tissue and play essential roles in tightly regulating these metabolic processes for homeostasis [19] . There is growing evidence that mitochondrial complex II is tightly associated with metabolic regulation at the molecular level, but less is known about its physiological significance. Here we show that complex II is an essential regulator of energy metabolism and plays important roles in orchestrating both glucose and fatty acid metabolism. To our surprise, liver-knockout SDHB mice are completely resistant to high fat diet induced obesity and showed complex II may be a candidate target for fighting obesity.
Results

Liver-specific knockout of SDHB shortens the lifespan in mice
To understand the critical role of complex II in mitochondrial respiration and regulating systemic energy metabolism, we created mice with knockout of SDHB, which is one subunit of complex II. The whole-body knockout of SDHB is embryonic lethal (Fig EV1A) , which indicates that complex II is essential for development. Given the central role of liver in systemic energy metabolism, we generated a liver-specific knockout of SDHB in mice ( Fig   1A-1C and Fig EV1B) (hereafter Sdhb -/-). These mice were viable at birth but died at about two months of age (Fig 1D) . The 5-week-old Sdhb -/-mice were completely normal in body weight and daily activities (Fig EV2A and EV2B) . However, the 8-week-old Sdhb -/-mice showed severe growth retardation, which started soon after weaning (Fig 1E and 1F) . Liver tissue analysis showed that ablation of SDHB resulted in the loss of complex II activity as assayed by complex II staining ( Fig 1I) and DCPIP test (Fig 1J) , even though the stability of the catalytic subunit, SDHA, was largely maintained (Fig 1H) . The assembly and stability of components of other OXPHOS complexes were unaffected (Fig 1G and 1H) . Furthermore, oxygen consumption ratio (OCR) analysis revealed that mitochondria from Sdhb -/-liver tissues did not respond to succinate (Fig 1K) , while the responses to malate and glutamate were unaffected (Fig 1L) . These results indicate that the activity of complex II was specifically ablated in the liver of Sdhb -/-mice, while the activity of other complexes was maintained.
Deficiency of complex II in liver accelerates glucose and fat consumption
Considering that complex II is an important component of Krebs cycle and OXPHOS for glucose metabolism, we first checked the serum glucose levels in 8-week-old mice. Intriguingly, the serum glucose level in Sdhb -/-mice was significantly lower than in Sdhb F/F mice (Fig 2A) . PAS (Periodic Acid-Schiff) staining also showed that Sdhb -/-mice had a lower level of glycogen in liver (Fig 2B and 2C) , indicating that glucose consumption may be increased in Sdhb -/-mice. To further validate this, mice were injected with glucose at the dosage of 2 g/kg body weight, then dynamic serum glucose concentrations were monitored and liver tissues were analyzed by PAS staining. The rate of glucose consumption was indeed higher in Sdhb -/-mice by glucose tolerance test (GTT) (Fig 2D) , while glycogen accumulation in Sdhb -/-mice was significantly inhibited (Fig 2E and 2F) . It was noticed that the levels of serum glucose and liver glycogen of 5-week-old Sdhb -/-mice were identical with those of Sdhb F/F controls (Fig EV2E and EV2F ). Taking these data together, we conclude that glucose catabolism is accelerated by the loss of complex II activities in 8-week-old mouse.
In addition to the drastic changes in glucose consumption in 8-week-old Sdhb -/-mice, we also observed that there was a significant decrease in the body fat ratio (Fig 2G) . Anatomic analysis showed that the masses of all white fat tissues (WAT), such as inguinal WAT (iWAT), scapular WAT (sWAT) and gonadal WAT (gWAT), and of brown adipose tissue (BAT), were dramatically decreased in Sdhb -/-mice (Fig 2H and 2I) . Furthermore, the adipocytes in all WAT and BAT tissues were reduced in size (Fig 2J) . Considering that the body fat ratio, adipose tissue mass, adipocyte size, and the staining of liver lipid droplets are identical in Sdhb -/-and control mice at 5 weeks of age ( Fig EV2H, EV2I and EV2J ), the decrease in fat tissue and adipocytes at 8 weeks of age may be due to increased lipid mobilization. Thus we checked the liver lipid levels in 8-week-old Sdhb -/-mice. Surprisingly, the levels of lipids were significantly reduced in the Sdhb -/-liver (Fig 2K and 2L) , suggesting that fatty acid catabolism may be also accelerated in liver.
Deficiency of SDHB in liver upregulates pathways involved in glucose and fat catabolism
To understand the molecular basis of these metabolic alterations in Sdhb -/-liver, we performed RNAseq analysis using livers from 8-week-old mice. The results showed that multiple genes involved in glycolysis, Krebs cycle and β-oxidation were upregulated in SDHB-deficient liver tissues (Fig 3A) . Western blotting analysis of liver samples from 8-week-old mice further confirmed that enzymes involved in glucose transportation, Krebs cycle, fatty acid β-oxidation and the gluconeogenesis pathway ( Fig 3B, 3C and 3D) were simultaneously upregulated. It is apparent that SDHB deficiency induces metabolic reprogramming which results in the enhanced catabolism of glucose and fats in Sdhb -/-tissues ( Fig 3E) . It is surprising that one key glycolytic enzyme, GCK, is downregulated at 8 weeks of age, as this is not in line with other results indicating accelerated glucose catabolism, such as lower serum glucose level (Fig 2A and 2D ) and liver glycogen accumulation (Fig 2B, 2C, 2E and 2F). To account for this discrepancy, we reasoned that the feeding status of the mice may affect the glycolytic pathway. Thus we examined the protein levels of the main glycolytic enzymes in the liver tissue of 5-week-old mice, at which time the serum glucose levels were normal in Sdhb -/-mice ( Fig EV2C) . Intriguingly, the levels of glycolytic enzymes were increased in Sdhb -/-mice at 5 weeks of age, and proteins involved in glucose transportation, Krebs cycle and fatty acid β-oxidation were also upregulated ( Fig EV2K) . It seems that the decrease in serum glucose levels affects the liver glycolysis levels in Sdhb -/-mice at 8 weeks of age. HIF1A is reported as a regulator of glucose metabolism in SDHB-deficient cells [20, 21] . Here we also found that HIF1A levels were high in Sdhb -/-mice at both 5 and 8 weeks of age (Fig 2A and Fig EV2K) . (Fig 4A) and growth retardation (Fig 4B and 4C) of Sdhb -/-mice, and levels of blood glucose were restored to the normal levels ( Fig 4D) . Anatomic analysis further showed that the body fat ratio (Fig 4E) , fat mass, and adipocyte size of WAT and BAT recovered to normal levels ( Fig 4F, 4G and 4H ). Liver fat accumulation was also increased in Sdhb -/-tissues (Fig 4I and 4J (Fig 5A and 5B) were fully restored. The HFD also led to recovery of the levels of blood glucose ( Fig 5C) and liver glycogen (Fig 5D and 5E) , and the body fat ratio (Fig 5G) . Along with improved serum glucose levels, the glucose intolerance of Sdhb -/-mice was decreased, even though glucose consumption was still higher than in HFD-treated Sdhb F/F mice (Fig 5F) . Moreover, HFD-treated Sdhb -/-mice had identical adipose tissue mass ( Fig 5H and 5I ), adipocyte size ( Fig 5J) and levels of liver fatty acid droplets (Fig 5K and 5L) as normal chow diet (CD)-fed mice. Lipid droplet levels in HFD-treated Sdhb -/-mice were also lower than HFD-treated Sdhb F/F mice, verifying the increased fatty acid catabolism in Sdhb -/-mice. Furthermore, western blotting analysis showed that glycolysis enzymes were all decreased, while enzymes in Krebs cycle, β-oxidation and gluconeogenesis were still increased, in Sdhb -/-mice when fed a HFD ( Fig 5M) . These results indicated that HFD-treated mice switched their metabolic pattern to the β-oxidation pathway, and serum glucose was maintained by gluconeogenesis. Taking these results together, we can conclude that complex II deficiency increases catabolism of energy substrates, and energy status can reprogram the metabolic pathways.
The restoration of Sdhb -/-phenotypes by HFD can be inhibited by Etomoxir
Etomoxir (ETO) is an inhibitor of β-oxidation which acts by inhibiting carnitine palmitoyltransferase I (CPT1) [22] . To examine whether fatty acid β-oxidation within mitochondria provides the vital energy sources for rescuing the phenotype of Sdhb -/-mice, we treated these mice with ETO under HFD conditions. The results showed that two-week ETO treatment significantly reduced the body weight (Fig 6A and 6B ) and serum glucose levels of HFD-treated Sdhb -/-mice ( Fig 6C) . Moreover, ETO treatment also dramatically inhibited fat consumption in Sdhb -/-liver tissues, so that the level of liver fat droplets was identical level to that in Sdhb F/F mice (Fig 6D and 6E ). This indicates that the process of HFD-induced energy compensation indeed depends on β-oxidation pathway. We also found that a high ETO dosage induced death in the Sdhb -/-mice due to a significant reduction in glucose levels, while no differences were seen in adipose tissue mass (Fig 6F and 6G ). Taken together, these results support our notion that HFD can indeed rescue the phenotypes of Sdhb -/-mice through the β-oxidation pathway.
Mice with loss function of complex II are resistant to HFD-induced obesity
Sdhb -/-mice have accelerated energy expenditure induced by high fatty acid catabolism, so we wondered if they were resistant to HFD-induced obesity. As expected, after treatment with a HFD for almost two years, the Sdhb -/-mice were strongly resistant to HFD-induced obesity compared with Sdhb F/F mice ( Fig 7A) . 
Discussion
Complex II lies at the crossroads of Krebs cycle and OXPHOS pathways, and is essential for cellular energy metabolism. In the current study, we generated SDHB liver-specific knockout mice and found that SDHB knockout abrogated the assembly and the activity of complex II Gene profiling reveals that the loss of complex II reprograms both glucose and fatty acid catabolism, resulting in acceleration of both. Loss of complex II upregulates the expression of genes involved in both glucose and fatty acid catabolism, and the levels of proteins involved in glucose transportation, glycolysis, Krebs cycle and β-oxidation. HIF1A is reported as a transcriptional factor for glucose metabolism and angiogenesis, and undergoes constitutive degradation by a process that involves a series of post-translational modifications [31] . It was shown that inactivation of SDH can induce a pseudohypoxia phenomenon, in which HIF1A is induced under normoxic conditions [20, 21] , and the stabilized HIF1A could increase glucose metabolism. Consistent with this theory, cells with complex II deficiency showed increased glucose consumption, including higher glucose uptake and glycolysis [24] . We also found increased HIF1A protein levels and upregulated glucose metabolism in Sdhb -/-mice.
Additionally, we found that Krebs cycle enzymes were upregulated, suggesting that residual enzyme activities are needed for coupling with the cell's metabolism. Our results are different from those of Kitazawa, who reported that in SDHB-knockout cultured cells there were no changes in protein levels, but there was bidirectional metabolic flow in Krebs cycle to maintain the necessary amounts of metabolites [24] . The discrepancy may be due to the reason that the cellular adaptive response is different between in vivo and in vitro. We were surprised to see the increased levels of proteins in the β-oxidation pathway, which indicated that fatty acids are mobilized as fuels to sustain the energy demand in Sdhb -/-mice. We also found increased levels of PPARA, which plays a major role in regulating β-oxidation by inducing expression of the gene encoding CPT1 [32] . The increased HIF1A and PPARA activity may underlie the metabolic reprogramming that increases the catabolism of both glucose and fatty acids. Further investigations are needed to clarify the precise pathways involved in these metabolic reprogramming events.
It is striking to find that supplementation with high levels of carbohydrate or fat completely reverses the phenotypes of Sdhb -/-mice. These dietary supplements restored the serum glucose level and lipid storage in addition to extending the lifespan and blocking body-weight loss. These data clearly showed that lipogenesis from glucose or gluconeogenesis from fatty acids were activated to maintain energy homeostasis. Increased levels of the gluconeogenesis core enzymes PCK1/2 may explain the restored serum glucose levels. These results indicate that complex II not only regulates glucose metabolism, but also fatty acid metabolism, and there exists a mutual compensatory relationship between the glucose and fat metabolism pathways. These findings also highlight that the liver is the metabolic center of the body, and orchestrates the whole body's energy use of glucose and fatty acids.
Imbalanced energy metabolism causes metabolic syndromes, which include central obesity, insulin resistance, glucose intolerance and non-alcoholic fatty liver disease. Together, these syndromes are among the greatest challenges to human health in the 21 st -century. Our studies show that there is compensation between energy sources and also between different organs, and offer a unique system to address the complex issue of energy storage and energy expenditure at the organism level. In obese patients, excess body fat is accumulated, which is harmful to cellular functions and causally related with many diseases. Intriguingly, we found that mice with complex II dysfunction are resistant to HFD-induced obesity, which is probably because the loss of complex II accelerates the expenditure of energy derived from both glucose and lipids. Our results thus suggest that complex II is an ideal target for accelerating cellular energy consumption to fight obesity. Future studies are warranted to further investigate the exact mechanisms through which complex II dysfunction regulates glucose and lipid metabolism, and to find new inhibitors that target complex II to fight obesity.
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Animals and ethics statement
All mice in this study were housed in the specific-pathogen free (SPF) facility in Nankai University. All germ-free animal diets, chow diet (CD), breeding diet (BD) and high-fat diet (HFD), were purchased from Beijing HFK Bioscience Co., Ltd. Energy supply ratios are listed in expanded view Table 2 .
Animal experiments
One-month-old mice were divided randomly into different groups. For sucrose treatment, mice had free access to CD and water supplemented with or without 20% sucrose. Body weights were measured every 3 days for 2 months. For HFD treatment, mice had free access to HFD and controls had free access to CD.
Body weights were measured every 3 days until the end of the experiments. For Etomoxir (ETO) treatment:
HFD-treated Sdhb F/F and Sdhb −/− mice were given intraperitoneal injections of Etomoxir (E124862-50, Aladdin) at a dose of 10 mg/kg dissolved in olive oil (BCBQ4885V, Sigma, USA) every 3 days for 3
weeks. Serum glucose was measured at 4 hours after injection, and after recording the viability, the livers of all mice were collected, and fixed or frozen to preserve them.
Sample collection
Mice were anesthetized and sacrificed by cervical dislocation. All adipose tissue and organs were isolated gently and weighed. Samples were divided into two parts and one part was frozen in liquid nitrogen while the other was fixed in 10% formalin.
Quantitative RT-PCR
RNA samples were kept in RNAlater buffer, frozen in liquid nitrogen and then stored in a -80℃ freezer.
Total mRNA from mouse tissues was extracted with Eastep Super Total RNA Extraction kits (0000278076, Promega). Reverse transcription was performed using M-MLV Reverse Transcriptase (M1705, Promega).
Expression of Sdha, Sdhb, Sdhc, Sdhd mRNA was analyzed with TransStar Top Green qPCR SuperMix (aq131-04, Trans) and normalized to the house-keeping gene Actb. All primers used for RT-qPCR are listed in expanded view Table 3 .
Isolation of mitochondria and OCR measurement
Anesthetized mice were sacrificed by cervical dislocation, and the liver was removed from the abdominal cavity, 30 mg fresh liver sample were homogenized in a Dounce Tissue Grinder in 1 mL liver mitochondrial isolation buffer I. After centrifuging 2 times at 600 g for 10 min, the supernatant was removed into a new tube and washed 3 times in isolation buffer II (buffer I without BSA) by centrifuging for 10 minutes at 10000 g. Isolated mitochondria were re-suspended in OCR measurement buffer and the concentration was adjusted to 1 mg/mL. After balancing, 20 μL of this mitochondrial suspension was added into the chamber followed by substrates such as succinate or malate and glutamate. ADP was added to initiate the reaction and oxygen consumption was recorded.
Blue native (BN)-PAGE
BN-PAGE was carried out as previously described [33, 34] and with some modifications. Gradient gels were prepared in our lab. Liver tissue was first homogenized in buffer I to give mitochondria at a concentration of 10 mg/ml, then the mitochondria were lysed in lysis buffer B (50 mM imidazole, 500 mM (1:1000, Tianjinsaier, SRP06209); antibody: SDHD (1:1000, Cloud-clone Corp., PAK214Mu01).
SDH activity assay
The DCPIP method was used to measure the activity of complex II with some modifications. Mitochondria were isolated and the concentration was adjusted to 1 mg/mL. A cuvette was filled with 
Primary hepatocyte isolation
Primary hepatocytes were isolated as previously described with some modifications, as follows. Mice were placed on the dissection board after anaesthetization and a winged needle was inserted into the inferior vena cava after opening the peritoneal cavity. The liver was washed by perfusion with washing buffer (pH 7.4, NaCl 8 g, KCl 0.4 g, NaH 2 PO 4 ·2H 2 O 0.078 g, Na 2 HPO 4 ·12H 2 O 0.151 g, NaHCO 3 0.35 g, EGTA 0.019 g, glucose 0.9 g, phenol red 0.006 g per 100 mL) for 20 minutes at a speed of 2 mL/min through the inferior vena cava. The hepatic portal vein was cut after the liver became swollen, and a new perfusion buffer was used (pH 7.4, NaCl 8 g, KCl 0.4 g, NaH 2 PO 4 ·2H 2 O 0.078 g, Na 2 HPO 4 ·12H 2 O 0.151 g, NaHCO 3 0.35 g, HEPES 2.38 g, phenol red 0.006 g, 2.5M CaCl 2 40μL, collagenase 10 mg per 100 mL) for 10 minutes at the same speed. The liver then became soft and was removed into a dish and hepatocytes were washed with DMEM medium and centrifuged for 3 minutes at 50 g and seeded in 6-well dishes at the concentration of 10 6 cells/well. Growth medium was DMEM with 10% FBS, penicillin/streptomycin, 100 nM insulin and 100 nM dexamethasone. Growth medium was changed after cell adhesion. Growth medium with or without palmate (PA) was added for the lipid consumption test; After 24 hours, medium was removed, the wells were washed with PBS for three times and the cells were fixed with 10% formalin for oil red staining.
Histology and chemical stains
For SDH staining, frozen sections of liver samples were incubated in 2.5 mL 0.01M phosphate buffer mixed with 2.5 mL 1M succinate solution and 2.5 mL DMSO containing 5 mg NTB for 15 minutes at room temperature. The sections were washed 3 times with PBS for 3 minutes and fixed in 10% formalin buffer for 5 minutes. The sections were washed again with ddH 2 O before mounting with glycogelatin. Oil
Red O staining was carried out as follows: primary isolated hepatocytes in 6-well plates or frozen liver sections were fixed in 10% formalin for 5 minutes, washed 3 times with ddH 2 
Glucose tolerance test and glucose measurement
Mice fasted for 4 hours were given intraperitoneal injections of glucose (2 g/kg body weight) for the glucose-tolerance test (GTT). Blood glucose was determined with an ACCU-CHEK glucometer (Roche), at 0, 15, 30, 60, 120 minutes after injection.
Glycogen accumulation assay
Sdhb −/− and Sdhb F/F mice fasted for 24 hours were divided into 3 groups. Intraperitoneal injections of glucose (2 g/kg body weight) were given to groups 2 and 3, while mice in group 1 were given intraperitoneal injections of ddH 2 O. Mice in groups 1, 2, and 3 were sacrificed at 0, 1.5, and 3 hours respectively and liver tissues were fixed in 10% formalin, then embedded in paraffin, sectioned, and stained PAS.
Statistical analysis
Values shown represent means ± SEM, p<0.05 was taken as statistically significant. C. Quantification of the intensity of PAS staining in B (n=4; at least ten microscope fields were examined for each liver section). B-E. Body sizes (B), body weight curves (C), serum glucose levels (D), and body fat ratios (E) in mice as described in A.
D. Glucose tolerance test (GTT) in
F. Images of the main adipose tissues (iWAT, sWAT, gWAT, and BAT) from mice as described in A.
G. Quantification of the masses of the adipose tissues shown in F (n=6; 6 microscope field for per adipose sections).
H. Representative images of adipocytes in iWAT, sWAT, gWAT and BAT. Scale bar: 50 μm.
I. Representative images showing Oil Red O staining of liver lipid droplets in mice as described in A. A. Survival curves of Sdhb F/F and Sdhb -/-mice treated with HFD or CD from 4 weeks of age to two years (n=6-9).
B-E. Body sizes (B), body weights (C), serum glucose levels (D) and body fat ratios (E) of mice as described in A.
F. Images of iWAT, sWAT, gWAT and BAT tissues of mice as described in A.
G. Quantification of the masses of the adipose tissues from F (n=6).
Expanded View Figures Figure EV1: Analysis of knock out Sdhb mice
A. Heterozygous whole-body Sdhb knockout mice were crossed with Sdhb F/F to generate Sdhb whole-body knockout mice and the pups were genotyped on the first day after birth. The pie chart shows the proportion of pups with each genotype (the numbers are shown in brackets).
B. SDHB protein levels in heart, liver, spleen, lung, kidney, intestine and brain of Sdhb F/F and liver-specific Sdhb -/-mice, GAPDH was used as loading control. 
